Study wrapper · #296
Relief of ovalbumin-induced airway remodeling by the glycyl-l-histidyl-l-lysine-Cu2+ tripeptide complex via activation of SIRT1 in airway epithelial cells.
Editor's note
A two-part study combining human observational data with a mouse model. In people, researchers reported that plasma GHK levels were lower in asthma patients than in age-matched controls, correlated moderately with a lung-function measure (FEF), and were lowest in those with fixed airflow limitation — an association, not causation, and vulnerable to confounding. In ovalbumin-sensitised asthmatic mice, exogenous GHK-Cu reduced airway collagen deposition, mucus secretion and epithelial-mesenchymal transition, with mechanistic work pointing to SIRT1 activation lowering TGF-β1. The mechanistic chain (GHK-Cu → SIRT1 → reduced TGF-β1 → less remodelling) is coherent and supported by in-vivo and in-vitro validation. But the causal efficacy evidence is entirely preclinical; the human component is only correlational. This connects to GHK-Cu's anti-inflammatory, matrix-modulating biology but represents a new indication with no controlled human trials. Human data are needed before clinical conclusions can be drawn.
Plain-language abstract
In severe asthma, the airways can become permanently narrowed through a process called airway remodeling. GHK is a natural peptide with anti-inflammatory and antioxidant properties. Researchers first measured GHK in the blood of asthma patients and found levels were lower than in similar healthy people; lower levels also tracked with worse lung-function readings and with fixed airway narrowing. This is a correlation and does not show that GHK causes or blocks the disease. Next, using mice sensitized to egg protein (ovalbumin) to model asthma, they gave GHK-Cu — a more absorbable copper-bound form — and reported less collagen buildup around the airways, less mucus, and reduced conversion of airway-lining cells into scar-like cells. Further experiments in mice and cells indicated GHK-Cu worked by raising the activity of a protein called SIRT1, which in turn lowered TGF-β1, a driver of tissue scarring. The authors conclude that low GHK is linked to airway narrowing in asthma and that adding GHK-Cu reduced remodeling in mice. Because the human part is only observational and the treatment was tested in mice, these findings cannot show whether GHK-Cu would help people with asthma.